References:

  1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. The. Lancet. 2007:1287-1301. 10.1016/S0140-6736(07)60601-1
  2. Hessheimer AJ, Vidal O, Valentini M, García-Valdecasas JC: Pheochromocytoma as a rare cause of arterial hypertension in a patient with autosomal dominant polycystic kidney disease: A diagnostic and therapeutic dilemma. International Journal of Surgery Case Reports. 2015:85-88. 10.1016/j.ijscr.2015.07.015
  3. Sedaia E, Esanu A, Ivanov V, et al.: Catecholamine-induced cardiomyopathy in a patient with pheochromocytoma and polycystic kidney and liver disease: a case report. European Heart Journal - Case Reports. 2019:062. 10.1093/ehjcr/ytz062
  4. Mansi L, Rambaldi PF, Marino G, Argenziano G, Sandomenico F, Vecchio ED. Pheochromocytoma Diagnosed With 1-123 MIBG Scintigraphy in a Patient With Concomitant Bilateral Polycystic Kidneys: CLINICAL NUCLEAR MEDICINE (1997: 22:268-270. 10.1097/00003072-199704000-00019
  5. Quiñonero Díaz A, García Hirschfeld J, Alonso Dorrego JM, Marchal Escalona C, Machuca Santa Cruz J, Marín Martín JA: Rotura esponánea de feocromocitoma en paciente con riñones poliquísticos: A propósito de un caso [Spontaneous rupture of pheochromocytoma in a patient with polycystic kidneys. Apropos of a case]. Archivos espanoles de urologia. 50:1117-9.
  6. Mete O, Asa SL, Gill AJ, Kimura N, De Krijger RR, Tischler A: Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022:90-114. 10.1007/s12022-022-09704-6
  7. Buffet A, Burnichon N, Favier J, Gimenez-Roqueplo A-P: An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. Best Practice & Research Clinical Endocrinology & Metabolism. 2020:101416. 10.1016/j.beem.2020.101416
  8. Pacak K: New Biology of Pheochromocytoma and Paraganglioma. Endocrine Practice. 2022:1253-1269. 10.1016/j.eprac.2022.09.003
  9. Al Subhi AR, Boyle V, Elston MS: Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years. Journal of the Endocrine Society. 2022:105. 10.1210/jendso/bvac105
  10. Lenders JWM, Kerstens MN, Amar L, et al.: Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension. 2020:1443-1456. 10.1097/HJH.0000000000002438
  11. Fagundes GFC, Almeida MQ: Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas. Journal of the Endocrine Society. 2022:004. 10.1210/jendso/bvac004
  12. Nazari MA, Hasan R, Haigney M, Maghsoudi A, Lenders JWM, Carey RM, Pacak K: Catecholamine-induced hypertensive crises: current insights and management. The. Lancet Diabetes & Endocrinology. 2023:942-954. 10.1016/S2213-8587(23)00256-5
  13. Aygun Nurcihan and Mehmet Uludag: Pheochromocytoma and paraganglioma: from treatment to follow-up. Sisli Etfal. 2020, 54,4:391-398. 10.14744/SEMB.2020.58998
  14. Kim Y, Yoo YC, Kim NY, Shin HJ, Kweon KH, Moon J, Kang S-W: The effects of perioperative dexmedetomidine infusion on hemodynamic stability during laparoscopic adrenalectomy for pheochromocytoma: a randomized study. Front Med. 2023:1276535. 10.3389/fmed.2023.1276535
  15. Bihain F, Nomine-Criqui C, Guerci P, Gasman S, Klein M, Brunaud L: Management of Patients with Treatment of Pheochromocytoma: A Critical Appraisal. Cancers. 2022:3845. 10.3390/cancers14163845
  16. Divya Mamilla, Katherine A. Araque, Alessandra Brofferio, Melissa K: Gonzales, James N. Sullivan, Naris Nilubol, Karel Pacak. Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. 2019:936. 10.3390/cancers11070936